for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG (ADR)

NVS

Latest Trade

88.96USD

Change

0.56(+0.63%)

Volume

1,771,681

Today's Range

88.78

 - 

89.27

52 Week Range

77.04

 - 

98.52

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
88.40
Open
89.12
Volume
1,771,681
3M AVG Volume
39.61
Today's High
89.27
Today's Low
88.78
52 Week High
98.52
52 Week Low
77.04
Shares Out (MIL)
2,245.09
Market Cap (MIL)
219,200.50
Forward P/E
14.11
Dividend (Yield %)
3.60

Next Event

Novartis AG at Berenberg US Conference (Virtual)

Latest Developments

More

Sandoz Confirms Late-Stage Clinical Development Plans For Proposed Biosimilar Aflibercept

Novartis Phase III Beovu Data Show Potential For Fluid Resolution In More Diabetic Macular Edema Patients With Fewer Injections Versus Aflibercept

Novartis Says Ilaris Receives Health Canada Approval As Treatment For Adult-Onset Still's Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG (ADR)

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Lead Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Steven Baert

Chief People & Organization Officer, Member of the Executive Committee

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

51.9K

2019

47.4K

2020

48.7K

2021(E)

51.9K
EPS (USD)

2018

5.150

2019

5.400

2020

5.780

2021(E)

6.303
Price To Earnings (TTM)
25.59
Price To Sales (TTM)
4.39
Price To Book (MRQ)
3.95
Price To Cash Flow (TTM)
15.25
Total Debt To Equity (MRQ)
74.82
LT Debt To Equity (MRQ)
54.23
Return on Investment (TTM)
8.68
Return on Equity (TTM)
6.50

Latest News

Latest News

Novartis biosimilar targets rivals' Eylea eye treatment

Novartis's generics arm Sandoz is set to enrol patients with neovascular age-related macular degeneration (nAMD) in a late-stage trial of a biosimilar version of Bayer and Regeneron's Eylea, Novartis said on Monday.

Novartis catches chill as mask wearing keeps flu at bay

Mask wearing during the pandemic kept the flu largely at bay this year, dampening Novartis's generic cough medicines business and helping drag the Swiss drugmaker's first-quarter profit below analyst expectations.

Novartis pushes back UK cholesterol study's end to 2026 on COVID disruption

Swiss drugmaker Novartis said on Tuesday that a large British study of its cholesterol-lowering drug Leqvio is now not expected to be completed until 2026, a year later than expected, as COVID-19 infections made participant recruitment difficult.

Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources

A Milan judge on Tuesday indicted the Italian units of Novartis and Bayer on charges of operating a scheme to cheat the regional public health service in Lombardy, legal and judicial sources said.

Novartis CEO says could boost CureVac vaccine production, if needed

Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference call on Tuesday.

Novartis Q1 sales, profit miss analyst expectations amid COVID-19 impact

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%, missing analyst expectations, as COVID-19 related lockdowns and disruptions in several geographies hit demand.

Novartis agrees to make ingredients Roche's Actemra for COVID-19 patients

Swiss drugmaker Novartis has signed a deal to make ingredients for Roche's Actemra treatment that is being repurposed for people with COVID-19, the company said on Thursday.

Roche, Novartis approvals in Europe signal more head-to-head competition

Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients.

RPT-UPDATE 1-Roche, Novartis approvals in Europe signal more head-to-head competition

Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients.

Novartis says Kesimpta gets EU approval in multiple sclerosis

Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

Novartis closes U.S. gene therapy site as Zolgensma sales fell from Q3 to Q4

Novartis is laying off 400 people and closing a U.S. gene therapy location that it bought only two years ago to make its $2.1 million per patient treatment Zolgensma as sales momentum for the most expensive one-time treatment stalled last year.

In-house counsel on the move: Fox and Novartis add lawyers

Companies in sectors from television to healthcare expanded their in-house legal teams this week, including media giant Fox Corp and Novartis, a key player in the race to manufacture a COVID-19 vaccine.

BioNTech to be given EU approval for Marburg COVID-19 vaccine plant - source

The European Union's drugs regulator is set to grant German biotech firm BioNTech approval for the use of COVID-19 vaccines produced at its new site in the German city of Marburg, a person familiar with the matter told Reuters on Friday.

Novartis corrects chairman's comments about kickbacks case

Novartis on Wednesday had to correct comments made by Chairman Joerg Reinhardt to a Swiss newspaper, because his portrayal of conduct that led to a $678 million U.S. settlement over kickbacks last year risked violating the agreement.

Novartis says radioligand therapy improves prostate cancer survival

Novartis' experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday.

Novartis radioligand therapy improves prostate cancer survival

Novartis' Lu-PSMA-617 radioligand therapy helped improve survival for patients with advanced castration-resistant prostate cancer in a phase III study, the Swiss drugmaker said on Tuesday.

Novartis, a key player in COVID-19 vaccine push, taps new chief legal officer

Novartis, a Swiss drugmaker that is helping Pfizer and BioNtech manufacture their COVID-19 vaccine, named Karen Hale its chief legal officer on Monday, after losing its top lawyer to rival Moderna earlier this month.

Novartis' canakinumab failed to improve survival in Phase III trial

Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing.

Novartis joins CureVac's vaccine contractor line-up

German biotech firm CureVac has enlisted Swiss pharmaceutical giant Novartis to help produce its experimental COVID-19 vaccine, boosting a network of contract manufacturers ahead of results from a pivotal trial.

Novartis and Bill & Melinda Gates Foundation collaborate on therapy for sickle cell disease

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation to fund the development of accessible single use gene therapies to cure sickle cell disease (SCD), the pharmaceuticals company said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up